Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
AstraZeneca
Express Scripts
US Army
Teva
Citi
Mallinckrodt
Harvard Business School
Argus Health

Generated: August 21, 2018

DrugPatentWatch Database Preview

Cumberland Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for CUMBERLAND PHARMS, and what generic alternatives to CUMBERLAND PHARMS drugs are available?

CUMBERLAND PHARMS has four approved drugs.

There are sixteen US patents protecting CUMBERLAND PHARMS drugs.

There are ninety patent family members on CUMBERLAND PHARMS drugs in twenty-five countries.

Summary for Cumberland Pharms
International Patents:90
US Patents:16
Tradenames:5
Ingredients:4
NDAs:4

Drugs and US Patents for Cumberland Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cumberland Pharms CALDOLOR ibuprofen SOLUTION;INTRAVENOUS 022348-001 Jun 11, 2009 DISCN No No 6,727,286 ➤ Try a Free Trial Y ➤ Try a Free Trial
Cumberland Pharms CALDOLOR ibuprofen SOLUTION;INTRAVENOUS 022348-002 Jun 11, 2009 RX Yes Yes 9,295,639 ➤ Try a Free Trial ➤ Try a Free Trial
Cumberland Pharms ACETADOTE acetylcysteine INJECTABLE;INTRAVENOUS 021539-001 Jan 23, 2004 AP RX Yes Yes 8,653,061 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for CUMBERLAND PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 200 mg/mL, 30 mL vials ➤ Subscribe 2012-04-04

Non-Orange Book US Patents for Cumberland Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,856,564 Condensed benzazepine derivative and pharmaceutical composition thereof ➤ Try a Free Trial
8,952,065 Acetylcysteine composition and uses thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Chubb
Julphar
Argus Health
Dow
Merck
Baxter
Healthtrust
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.